Key result
Self-managed oral anticoagulant therapy with vitamin K antagonists is advocated for broader clinical implementation to prevent thromboembolic events.
The authors call for the implementation of self-managed oral anticoagulant therapy with vitamin K antagonists.
Answers are grounded in this paper and cite their sources.
Self-managed VKA therapy should not yet change practice; leaves open need for randomized trials to confirm safety and efficacy.
Oral anticoagulant therapy (OAT) with vitamin K antagonists (VKA), for example, warfarin or phenprocoumon, remains the mainstay to prevent thromboembolism in a variety of clinical conditions. Mecha...
No takes yet. Share an insight, caveat, or question.
Christensen et al. (2016) studied this question. Self-managed oral anticoagulant therapy with vitamin K antagonists is advocated for broader clinical implementation to prevent thromboembolic events.
Synapse has enriched 10 related papers. Consider them for comparative context: